UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression

Frontiers in immunology, 2022-04, Vol.13, p.850856-850856

2022

Link zum Volltext

Verfügbarkeit prüfen

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4019-4019

2020

Link zum Volltext

Verfügbarkeit prüfen

Nouvelles AMMs : pemigatinib dans les cholangiocarcinomes avec fusion ou réarrangement de FGFR2

Bulletin du cancer, 2021-05, Vol.108 (5), p.446-447

2021

Link zum Volltext

Verfügbarkeit prüfen

Adénocarcinome œsogastrique – nouvelles cibles thérapeutiques

Bulletin du cancer, 2023-05, Vol.110 (5), p.560-569

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3599-3599

2023

Link zum Volltext

Verfügbarkeit prüfen

Stratégie thérapeutique séquentielle : promesses et difficultés

Bulletin du cancer, 2021-05, Vol.108 (5), p.443-445

2021

Link zum Volltext

Verfügbarkeit prüfen

First in class TLR7/8 agonist BDB001 combined with atezolizumab and stereotactic body radiation therapy in patients with advanced pancreatic adenocarcinoma: Results from the AGADIR study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4153-4153

2023

Link zum Volltext

Verfügbarkeit prüfen

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

European journal of cancer (1990), 2024-05, Vol.202, p.114033-114033, Article 114033

2024

Link zum Volltext

Verfügbarkeit prüfen

CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2703-TPS2703

2022

Link zum Volltext

Verfügbarkeit prüfen

REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.4125-4125

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

British journal of cancer, 2022-04, Vol.126 (6), p.969-969

2022

Link zum Volltext

Verfügbarkeit prüfen

Skeletal muscle loss under chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4025-4025

2020

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

British journal of cancer, 2022-06, Vol.126 (10), p.1394-1400

2022

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in subjects with thoracic or extra-thoracic malignancy

Clinics and research in hepatology and gastroenterology, 2022-03

2022

Link zum Volltext

Verfügbarkeit prüfen

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer: Plasma clearance of RAS mutation in colorectal cancer

International journal of cancer, 2019-08

2019

Link zum Volltext

Verfügbarkeit prüfen

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study

International journal of environmental research and public health, 2023-05, Vol.20 (11), p.5949

2023

Link zum Volltext

Verfügbarkeit prüfen

Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should mutation research be recommended in everyday practice?

Therapeutic advances in gastroenterology, 2024-01, Vol.17

2024

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Docetaxel, Fluorouracil and Oxaliplatin or Cisplatin with Other Modified Schedules: a New Therapeutic Index in Advanced Gastric Cancer

Annals of oncology, 2013-06, Vol.24, p.iv19-iv20

2013

Link zum Volltext

Verfügbarkeit prüfen

Furin Prodomain ppFurin Enhances Ca 2+ Entry Through Orai and TRPC6 Channels' Activation in Breast Cancer Cells

Cancers, 2021-04, Vol.13 (7)

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of second-line intra-arterial 5FU or mitomycine C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15061-e15061

2017

Link zum Volltext

Verfügbarkeit prüfen

Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.370-370

2018

Link zum Volltext

Verfügbarkeit prüfen

Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT or ACT trial)

Journal of clinical oncology, 2019-02, Vol.37 (4_suppl), p.626-626

2019

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15048-e15048

2015

Link zum Volltext

Verfügbarkeit prüfen

Impact of antiangiogenic treatments on exhausted PD-1 + T lymphocytes in colorectal cancer

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e22121-e22121

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(54)
Bücher
(1)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression

REGOMUNE: A phase II study of regorafenib plus avelumab in solid tumors—Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort

Nouvelles AMMs : pemigatinib dans les cholangiocarcinomes avec fusion ou réarrangement de FGFR2

Adénocarcinome œsogastrique – nouvelles cibles thérapeutiques

Targeting EZH2 to overcome the resistance to immunotherapy in microsatellite stable colorectal cancer: Results from the CAIRE study

Stratégie thérapeutique séquentielle : promesses et difficultés

First in class TLR7/8 agonist BDB001 combined with atezolizumab and stereotactic body radiation therapy in patients with advanced pancreatic adenocarcinoma: Results from the AGADIR study

A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors

REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors—Results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort

Correction to: Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

Skeletal muscle loss under chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study

Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study

Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study

Diagnostic accuracy and clinical impact of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in Positron Emission Tomography - Computed Tomography (PET-CT)-positive mediastinal lymphadenopathies in subjects with thoracic or extra-thoracic malignancy

Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer: Plasma clearance of RAS mutation in colorectal cancer

One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study

Echoendoscopic ultrasound pancreatic adenocarcinoma diagnosis and theranostic approach: should mutation research be recommended in everyday practice?

Comparison of Docetaxel, Fluorouracil and Oxaliplatin or Cisplatin with Other Modified Schedules: a New Therapeutic Index in Advanced Gastric Cancer

Furin Prodomain ppFurin Enhances Ca 2+ Entry Through Orai and TRPC6 Channels' Activation in Breast Cancer Cells

Efficacy and tolerability of second-line intra-arterial 5FU or mitomycine C after intra-arterial oxaliplatin failure in patients with colorectal cancer and unresectable liver metastases

Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice

Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT or ACT trial)

Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO

Impact of antiangiogenic treatments on exhausted PD-1 + T lymphocytes in colorectal cancer

Aktive Filter

Suchergebnisse filtern